Results · Apr-Jun 2026 · filed 12 Aug 2026
Caplin Point Laboratories Q1 FY27 results
Sales grew 20% to ₹610 crore from ₹510 crore in Apr-Jun 2025.
Operating profit grew 20% to ₹213 crore, an operating margin of 35.0% (up 0.1 points from a year ago).
Net profit grew 19% to ₹179 crore from ₹151 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +2%, net profit +4%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 610.4 | 510.2 | +20% |
| Operating profit (EBITDA) | 213.5 | 177.8 | +20% |
| Operating margin | 35.0% | 34.8% | +0.1 pts |
| Net profit | 179.1 | 150.8 | +19% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Change in Management
- 12 Aug 2026Results For Quarter Ended June 30, 2026
- 12 Aug 2026Corporate Action-Board approves Dividend
- 12 Aug 2026Board Meeting Outcome for Meeting Held On August 12, 2026
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.